Combination therapy: The Holy Grail for the treatment of postmenopausal osteoporosis?

Current Medical Research and Opinion

Volumn 27, Issue 7, 2011, Pages 1493-1497

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Bone density; Combination; Fracture; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE REMODELING; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OSTEOGENESIS; OSTEOPOROSIS, POSTMENOPAUSAL; STANDARD OF CARE;

EID: 79958777282     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.591783     Document Type: Review

References (26)

1. Burr DB. Targeted and nontargeted remodeling. Bone 2002;30:2-4. (Pubitemid 34044293)
2. Heaney RP. Remodeling and skeletal fragility. Osteoporos Int 2003; 14(Suppl 5):S12-S15.
3. McClung MR, San MJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8. (Pubitemid 41138965)
4. Johnell O, Scheele W, Lu Y, et al. Additive effects of raloxifene and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:985-92. (Pubitemid 36121052)
5. Greenspan SL, Resnick NM, Parker RA. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 2003;289:2525-33. (Pubitemid 37430154)
6. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. [See comments.] J Clin Endocrinol Metab 2001;86:1890-7. (Pubitemid 32472892)
7. Meschia M, Brincat M, Barbacini P, et al. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women. Calcif Tissue Int 1993;53:17-20. (Pubitemid 23187326)
8. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15. (Pubitemid 37152030)
9. Finkelstein JS, Wyland JJ, Lee H, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2010;95:1838-45.
10. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003;349:1216-26. (Pubitemid 37152031)
11. Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month doubleblind placebo-controlled trial. J Bone Miner Res 2005;20:1905-11. (Pubitemid 41532775)
12. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-5. (Pubitemid 27348431)
13. Cosman F, Nieves J, Woelfert L, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res 2001; 16:925-31. (Pubitemid 32332303)
14. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res 2011;26:503-11.
15. Ettinger B, San MJ, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19:745-51. (Pubitemid 41094385)
16. Miller PD, Delmas PD, Lindsay R, et al. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 2008;93:3785-93.
17. Cosman F, Wermers RA, Recknor C, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab 2009;94:3772-80.
18. Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 2005; 353:555-65. (Pubitemid 41138937)
19. Rittmaster RS, Bolognese M, Ettinger MP, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 2000;85:2129-34. (Pubitemid 32269232)
20. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992-7. (Pubitemid 40064654)
21. Finkelstein JS, Wyland JJ, Leder BZ, et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009;94:2495-501.
22. Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566-75. (Pubitemid 41138938)
23. Cosman F, Nieves JW, Zion M, et al. Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate. J Bone Miner Res 2009;24:1110-15.
24. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68. (Pubitemid 38133766)
25. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25:937-47.
26. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011;26:19-26.